United Kingdom
Cannabis-based products for medical use
Thanks to deep scientific expertise, rigorous process management and quality control, EMMAC ensures MHRA medical-grade quality products with the full accreditation of relevant regulatory certifications for its manufacturing, distribution and supply processes.
Cutting-edge research
In partnership with leading European academic institutions including Imperial College London, EMMAC is at the forefront of research to deliver clinical data regarding the efficacy of medical cannabis for pain and the potential health benefits for patients.
End-to-end control
At EMMAC Life Sciences Group, we control the entire lifecycle of our medical cannabis – from cultivation and extraction to production and distribution.
People & expertise
EMMAC’s board and management team comprise of seasoned industry executives and consultants. Every member brings with them a wealth of knowledge and experience – from a range of scientific, medical, technical and FMCG backgrounds.
EMMAC announces pioneering research collaboration with Imperial College London
EMMAC Across Europe
EMMAC has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabis but also a European leader in the production and supply of medical cannabis, hemp and other derivative products.
Press Releases
EMMAC Life Sciences Group announces UK manufacture of medical cannabis
16 October 2020, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company,
EMMAC secures GDP licence for Swiss pharmaceutical entity, EMMAC SAGL
18 August 2020, London. EMMAC Life Sciences Group, Europe’s largest independent cannabis company, is pleased to announce that EMMAC SAGL,
Medalchemy receives licence for cultivation of medical cannabis. Spanish EU GMP Facility now has licences to cultivate, extract and manufacture cannabis extract
28 July 2020, London. EMMAC Life Sciences Group, Europe’s largest independent cannabis company, is pleased to announce that Medalchemy, the
Andina Acquisition Corp. III and EMMAC Life Sciences Limited Announce Signing of Non-Binding Letter of Intent for Business Combination
22nd July 2020 EMMAC is the Largest Independent European Cannabis Company with Low-Cost Cultivation, EU-GMP Manufacturing and Processing, and an
EMMAC to manufacture product for COVID-19 clinical trial
26 May 2020, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that Medalchemy, the
EMMAC becomes first European cannabis company licensed to manufacture medical cannabis APIs with THC
19 May 2020, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that Medalchemy, the
Stay informed
Fill in the form below to receive the latest news and developments in medical cannabis from EMMAC
